The efficacy of maintenance mirvetuximab soravtansine plus bevacizumab is being compared with bevacizumab alone in patients with folate receptor alpha–positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancers that did not progress on second-line triplet therapy in the phase 3 GLORIOSA study.
The dynamics of the CDKL5 deficiency disorder market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases
The global large granular lymphocytic leukemia (LGLL) therapeutics market is expected to surpass an impressive valuation of US$ 2,871.05 million in 2023 and is projected to reach US$ 12,700 million by 2033, trailing a CAGR of 16.03% In addition, the increasing research and development activities and technological de.
Glioblastoma Multiforme Treatment Market Analysis by Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy), by Drug Class (Temozolomide,.